Cargando…
Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model
OBJECTIVES: Menopause is often characterized by detrimental metabolic changes, such as obesity, insulin resistance, and impaired glucose tolerance, often requiring treatment. KeyBioscience Peptides (KBPs) are Dual Amylin and Calcitonin Receptor Agonists which have shown promising metabolic effects i...
Autores principales: | Katri, Anna, Reker, Ditte, Karsdal, Morten A., Bay-Jensen, Anne-Christine, Henriksen, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284344/ https://www.ncbi.nlm.nih.gov/pubmed/33399320 http://dx.doi.org/10.1097/GME.0000000000001722 |
Ejemplares similares
-
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
por: Sonne, Nina, et al.
Publicado: (2020) -
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy
por: Sonne, Nina, et al.
Publicado: (2022) -
Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model
por: Katri, Anna, et al.
Publicado: (2019) -
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021) -
KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
por: Andreassen, K.V., et al.
Publicado: (2021)